Source comparison
TB-500 Fibrosis Reduction Complete Guide 2026: Comparison of Anti-Fibrotic Mechanisms
Before selecting TB-500 for fibrosis research, understanding how its mechanism compares to other anti-fibrotic compounds clarifies its unique advantages and limitations. TB-500 BMP-7 upregulation + MMP activation Blocks SMAD2/3, activates SMAD1/5/8 40–50% redu
This comparison does not assign a generated winner or score.
- Before selecting TB-500 for fibrosis research, understanding how its mechanism compares to other anti-fibrotic compounds clarifies its unique advantages and limitations.
- TB-500
- BMP-7 upregulation + MMP activation
- Blocks SMAD2/3, activates SMAD1/5/8
- 40–50% reduction in 6–8 weeks
- Twice weekly SC
- Most effective when initiated during inflammatory-to-fibrotic transition; reverses established fibrosis via MMP activity. Not just prevention
- Pirfenidone
- TGF-β1 synthesis inhibition + antioxidant
- Reduces SMAD2/3 phosphorylation
- 25–35% reduction in 8–12 weeks
- Daily oral
- FDA-approved for idiopathic pulmonary fibrosis; works via TGF-β1 suppression but doesn't actively promote matrix degradation
- Losartan (ARB)
- Angiotensin II receptor blockade
- Indirect: reduces TGF-β1 expression
- 20–30% reduction in 8–12 weeks
- Cardiovascular drug with anti-fibrotic side benefit; effective in hypertensive fibrosis models but weaker in non-renin-angiotensin-driven fibrosis
- BMP-7 (recombinant)
- Direct BMP-7 receptor agonism
- Activates SMAD1/5/8
- 35–45% reduction in 6–8 weeks
- 2–3× weekly SC
- Expensive to produce; TB-500 induces endogenous BMP-7 rather than requiring exogenous protein
- Tranilast
- TGF-β1 release inhibition from mast cells
- Reduces SMAD2/3 signaling
- 15–25% reduction in 8–10 weeks
- Approved in Japan for keloid treatment; mechanism limited to mast cell-mediated fibrosis